Rituximab after methotrexate failure in rheumatoid arthritis: Evaluation of the SERENE trial

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1515-1518

  Khan, Abdul ^a   Scott, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Methotrexate inadequate responders; Rheumatoid arthritis; Rituximab; SERENE trial; Seropositive and seronegative rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB;

ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SHORT FORM 36; TREATMENT RESPONSE;

EID: 80053650191     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.608061     Document Type: Article

References (11)

1. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35
2. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8
3. Edwards J, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81 (Pubitemid 38758544)
4. Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2010;published online 156 May 2010; doi: 10.1007/s00296-010-1526-y
5. Bagust A, Boland A, Hockenhull J, et al. Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess 2009;13(Suppl 2):23-9
6. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400
7. Pyrpasopoulou A, Douma S, Triantafyllou A, et al. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther 2010;14:43-8
8. van Vollenhoven RF, Emery P, Bingham CO III, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67
9. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816-24
10. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46
11. Kingsley GH, Khoshaba B, Smith CM, et al. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria. Rheumatology 2005;44:629-32 (Pubitemid 41487232)